MAPT and Alzheimer disease: First, we analyzed the immunoreactivity of BDTOs from both AD and NDAN subjects to the recombinant monoclonal anti‐tau and to the anti‐oligomeric tau antibodies T22 and TOMA2, respectively, comparing them to a standard curve of recombinant TauO (rTauO) of known concentrations (Figure 2B).